Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase
Eun‐Ji Choi
Blood Research (2023) Vol. 58, Iss. S1, pp. S29-S36
Open Access | Times Cited: 19

Showing 19 citing articles:

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors
Sahil Hussain, Mohd Mursal, Garima Verma, et al.
European Journal of Pharmacology (2024) Vol. 970, pp. 176484-176484
Closed Access | Times Cited: 11
Safety and Efficacy of Asciminib in Chronic Myeloid Leukemia Patient with Chronic Kidney Diseases: A Case Report
Awni Alshurafa, Afshan Adil, Mohamed A. Yassin
Case Reports in Oncology (2024) Vol. 17, Iss. 1, pp. 96-100
Open Access | Times Cited: 5
Transforming hematological research documentation with large language models: an approach to scientific writing and data analysis
John Yang, Sang‐Hyun Hwang
Blood Research (2025) Vol. 60, Iss. 1
Open Access
Asciminib: the tyrosine kinase inhibitor with a unique mechanism of action
Akriti G Jain, Jorge E. Cortés
Expert Opinion on Pharmacotherapy (2025)
Closed Access
Current and future of targeted therapies against BCR::ABL kinases
Jayavel Sridhar, M. Subramanian, Pradeep Kumar Kesavan, et al.
Journal of the Egyptian National Cancer Institute (2025) Vol. 37, Iss. 1
Open Access
Impact of solvation on plant-derived cyclic octapeptide alkaloid reactivity and drug suitability against target proteins implicated in leukemia: DFT, pharmacokinetics and molecular docking studies
Obinna C. Godfrey, Eze A. Adindu, Joy Chinweokwu Ugwu, et al.
Journal of Molecular Structure (2025), pp. 142504-142504
Closed Access
Protein lipidation in the tumor microenvironment: enzymology, signaling pathways, and therapeutics
Mengke Xu, Bo Xu
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Structure and Dynamics of the ABL1 Tyrosine Kinase and Its Important Role in Chronic Myeloid Leukemia
Ayca Irgit, Reyhan Kamıs, Belgin Sever, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 5
Open Access
Genetic Landscape of Chronic Myeloid Leukemia and a Novel Targeted Drug for Overcoming Resistance
Ryo Yoshimaru, Yosuke Minami
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13806-13806
Open Access | Times Cited: 6
Chronic Myeloid Leukemia with a Rare Philadelphia Chromosome Variant Involving Chromosome 16
Salem Bahashwan
American Journal of Case Reports (2024) Vol. 25
Closed Access | Times Cited: 1
Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib
Zhijing Liu, Dongzhi Wu, Chengjie Ke, et al.
Oncology (2024), pp. 1-13
Closed Access | Times Cited: 1
CML 25 Years Later — Poised for Another Breakthrough?
Elisabetta Abruzzese
New England Journal of Medicine (2024) Vol. 391, Iss. 10, pp. 955-957
Closed Access | Times Cited: 1
Cyclic Peptides as Protein Kinase Modulators and Their Involvement in the Treatment of Diverse Human Diseases
Lorena Martínez-Alcántar, Laura Hernández-Padilla, Alma Laura Díaz-Pérez, et al.
Kinases and Phosphatases (2024) Vol. 2, Iss. 4, pp. 346-378
Open Access | Times Cited: 1
Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia
Noor E. Verhagen, Jan J. Koenderink, Nicole M. A. Blijlevens, et al.
Pharmaceutics (2023) Vol. 15, Iss. 11, pp. 2535-2535
Open Access | Times Cited: 1
Asciminib a new player in treatment of TKI-resistant/intolerant chronic phase chronic myelogenous leukemia
Krzysztof Lewandowski
Acta Haematologica Polonica (2024) Vol. 55, Iss. 2, pp. 62-72
Open Access
Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia
Andrew Wu, Liu Xiao-hu, Clark Fruhstorfer, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3307-3307
Open Access
Asciminib Use Highlighting Underlying Moyamoya Disease: A Case Report
Saloni Savani, Arpita Pawa, Naved Salim, et al.
Cureus (2024)
Open Access
A comprehensive review on synthetic strategy and MOA of marketed drugs having therapeutically potential chemical entity pyrazole
Sucheta Singh, Kuldeep Singh, Sumit Tahlan
Journal of the Iranian Chemical Society (2024)
Closed Access
Safety and efficacy of asciminib in a patient with chronic myeloid leukemia on hemodialysis
Ryosuke Naka, Yoshimitsu Shimomura, Masatomo Miura, et al.
International Journal of Hematology (2024)
Closed Access
Page 1

Scroll to top